NICE’s positive final guidance for Agamree follows confirmation that no appeals were submitted against its positive December ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on SLDB stock, giving a Buy rating yesterday.Stay Ahead of the ...

William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating on January 13.Stay Ahead of the ...

Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

The landscape of rare diseases is constantly changing as new ailments and conditions are identified and reported regularly.

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the design and development ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

An accident and a malfunction render both of columnist Betty Vertin's accessible vans useless, leaving the family without transportation.

This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch ...